Monument Therapeutics Strengthens Leadership with New Chair and Advisory Board Members

Monument Therapeutics' Leadership Evolution

In a significant expansion of its leadership team, Monument Therapeutics, a key player in the neuroscience drug development space, recently announced the appointment of Robert Radie as Non-Executive Chair of the Board, alongside Dr. Heather Preston's addition to the advisory board. This strategic move, hailed as a pivotal moment for the company, aims to bolster its growth trajectory and advance its innovative approaches in treating central nervous system (CNS) disorders.

The Profile of Robert Radie

Robert S. Radie (commonly known as Bob) is recognized for his extensive experience, spanning over 30 years in both public and private pharmaceutical and biotech sectors. His career kicked off at Eli Lilly, where he contributed to the launch of highly successful antidepressants and antipsychotics. Radie’s leadership has played a critical role in the commercial success of notable companies in the neuroscience sector, including Prestwick Pharmaceuticals and Zyla Life Sciences.

Currently, he serves as CEO and Chair of Neuraptive Therapeutics, which specializes in nerve injury treatments. His impressive past also includes pivotal roles such as President and CEO of Topaz Pharmaceuticals, which was acquired by Sanofi Pasteur, and Transmolecular, Inc., a biotechnology company focused on developing cancer diagnostics and treatments. Radie has also held senior positions at companies like Morphotek and Vicuron Pharmaceuticals, in addition to serving on several boards, including Orcosa and Rockwell Medical.

With Radie’s wealth of operational experience and a proven success record in neuroscience, Monument is well-positioned to scale and amplify its therapeutic pipeline.

Welcoming Dr. Heather Preston

Joining Bob on the advisory board is Dr. Heather Preston, whose background merges medicine with management consulting. With over two decades of experience in healthcare venture capitalism, Dr. Preston's insights are expected to be invaluable, particularly in clinical development and investment strategies. She has a profound interest in advancing treatments for schizophrenia and previously served on the Board of Karuna Therapeutics, which was acquired by Bristol Myers Squibb for an astonishing $14 billion in 2024.

Dr. Jenny Barnett, the CEO of Monument Therapeutics, expressed her enthusiasm, emphasizing how both appointments align with the company's mission of transforming CNS disorder treatment. “Bob’s extensive operational experience in the field will be crucial as we expand, while Heather’s strategic knowledge will fortify our advisory board during this pivotal phase for our leading programs,” she stated.

Monument Therapeutics: A Forward-Thinking Approach

Headquartered in Manchester, UK, Monument Therapeutics stands at the forefront of neuroscience-focused drug development. The company employs a distinctive novel drug development approach that utilizes digital cognitive assessments to identify patients who are best suited for innovative therapies. This precision psychiatry method not only reflects the company’s commitment to personalized medicine but also positions it as a leader in a competitive field.

As Monument Therapeutics continues to push the boundaries of psychiatric and neurological treatment innovations, the strategic additions of Robert Radie and Heather Preston to its leadership and advisory teams signify a promising era in its quest to enhance the lives of individuals grappling with CNS disorders.

For more information about Monument Therapeutics, visit www.monumenttx.com.